TYK2
Non-receptor tyrosine-protein kinase TYK2
As of the edition of 20 October 2026, TYK2 (non-receptor tyrosine-protein kinase TYK2, UniProt P29597) has 14 drugs tested at it and 19 companies on the list, 3 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P29597
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 52
- Disease areas
- Skin and connective tissue; Immune system; Bones, joints and muscles; Digestive system; Cancer; Blood and lymph; Inherited and neonatal; Lungs and airways
- Registered trials of its drugs
- 525
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 2 |
| Stopped | 5 |
| Status not established | 1 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tofacitinib | Marketed | Phase 4 | Ends 2028 |
| Cravacitinib | Marketed | Phase 4 | Ends 2033 |
| Filgotinib | Marketed | Phase 4 | none listed |
| Peficitinib | Marketed | Phase 3 | none listed |
| Brepocitinib | Marketed | Phase 3 | none listed |
| Zasocitinib | Active | Phase 3 | none listed |
| Delgocitinib | Marketed | Phase 3 | Ends 2031 |
| D-2570 | Active | Phase 3 | none listed |
| Gusacitinib | Stopped | Phase 2 | none listed |
| Izencitinib | Stopped | Phase 3 | none listed |
| ESK-001 | Stopped | Phase 2 | none listed |
| Ropsacitinib | Stopped | Phase 2 | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 5 |
| Engaged | 4 |
| Undetermined | 7 |
| Total on the list | 19 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Bristol Myers Squibb | Route B |
| Gilead Sciences | Route B |
The other 16 companies at TYK2
In the product19 companies in all; 16 are not named here, and no score is.
See the 19 companies at TYK2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.